Jiangsu Sihuan Bioengineering Co Ltd (000518) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangsu Sihuan Bioengineering Co Ltd (000518) has a cash flow conversion efficiency ratio of 0.104x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.43 Million ≈ $5.92 Million USD) by net assets (CN¥388.58 Million ≈ $56.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jiangsu Sihuan Bioengineering Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Jiangsu Sihuan Bioengineering Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jiangsu Sihuan Bioengineering Co Ltd (000518) total liabilities for a breakdown of total debt and financial obligations.
Jiangsu Sihuan Bioengineering Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Sihuan Bioengineering Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perspective Therapeutics Inc.
NYSE MKT:CATX
|
-0.067x |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
0.033x |
|
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
|
0.134x |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
0.003x |
|
Vestum AB (publ)
ST:VESTUM
|
0.014x |
|
Bahnhof AB Series B
ST:BAHN-B
|
0.072x |
|
Guangdong Huafeng New Energy Technology Co Ltd
SHE:002806
|
-0.043x |
|
OPTHEA LTD
F:UKJ
|
N/A |
Annual Cash Flow Conversion Efficiency for Jiangsu Sihuan Bioengineering Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Sihuan Bioengineering Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Jiangsu Sihuan Bioengineering Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥398.97 Million ≈ $58.38 Million |
CN¥1.46 Million ≈ $213.84K |
0.004x | +15.25% |
| 2023-12-31 | CN¥512.78 Million ≈ $75.04 Million |
CN¥1.63 Million ≈ $238.47K |
0.003x | -61.24% |
| 2022-12-31 | CN¥593.50 Million ≈ $86.85 Million |
CN¥4.87 Million ≈ $712.02K |
0.008x | +3306.67% |
| 2021-12-31 | CN¥646.78 Million ≈ $94.64 Million |
CN¥155.65K ≈ $22.78K |
0.000x | -99.84% |
| 2020-12-31 | CN¥685.05 Million ≈ $100.24 Million |
CN¥100.23 Million ≈ $14.67 Million |
0.146x | +64.78% |
| 2019-12-31 | CN¥660.31 Million ≈ $96.62 Million |
CN¥58.63 Million ≈ $8.58 Million |
0.089x | +152.93% |
| 2018-12-31 | CN¥642.80 Million ≈ $94.06 Million |
CN¥22.57 Million ≈ $3.30 Million |
0.035x | +319.88% |
| 2017-12-31 | CN¥675.54 Million ≈ $98.85 Million |
CN¥-10.79 Million ≈ $-1.58 Million |
-0.016x | -184.26% |
| 2016-12-31 | CN¥611.10 Million ≈ $89.42 Million |
CN¥11.58 Million ≈ $1.69 Million |
0.019x | +108.47% |
| 2015-12-31 | CN¥608.69 Million ≈ $89.07 Million |
CN¥-136.11 Million ≈ $-19.92 Million |
-0.224x | -903.20% |
| 2014-12-31 | CN¥721.59 Million ≈ $105.59 Million |
CN¥20.09 Million ≈ $2.94 Million |
0.028x | +207.00% |
| 2013-12-31 | CN¥730.78 Million ≈ $106.94 Million |
CN¥-19.02 Million ≈ $-2.78 Million |
-0.026x | -139.59% |
| 2012-12-31 | CN¥830.24 Million ≈ $121.49 Million |
CN¥54.56 Million ≈ $7.98 Million |
0.066x | +199.90% |
| 2011-12-31 | CN¥915.76 Million ≈ $134.00 Million |
CN¥20.07 Million ≈ $2.94 Million |
0.022x | -91.68% |
| 2010-12-31 | CN¥879.72 Million ≈ $128.73 Million |
CN¥231.62 Million ≈ $33.89 Million |
0.263x | +229.06% |
| 2009-12-31 | CN¥712.38 Million ≈ $104.24 Million |
CN¥57.00 Million ≈ $8.34 Million |
0.080x | -19.30% |
| 2008-12-31 | CN¥692.86 Million ≈ $101.39 Million |
CN¥68.69 Million ≈ $10.05 Million |
0.099x | +207.07% |
| 2007-12-31 | CN¥833.76 Million ≈ $122.01 Million |
CN¥26.92 Million ≈ $3.94 Million |
0.032x | +187.62% |
| 2006-12-31 | CN¥1.01 Billion ≈ $147.97 Million |
CN¥-37.26 Million ≈ $-5.45 Million |
-0.037x | -581.72% |
| 2005-12-31 | CN¥1.00 Billion ≈ $146.76 Million |
CN¥-5.42 Million ≈ $-793.25K |
-0.005x | -111.07% |
| 2004-12-31 | CN¥1.11 Billion ≈ $161.96 Million |
CN¥54.05 Million ≈ $7.91 Million |
0.049x | -35.47% |
| 2003-12-31 | CN¥1.10 Billion ≈ $160.34 Million |
CN¥82.91 Million ≈ $12.13 Million |
0.076x | -53.23% |
| 2002-12-31 | CN¥1.06 Billion ≈ $155.49 Million |
CN¥171.92 Million ≈ $25.16 Million |
0.162x | +441.00% |
| 2001-12-31 | CN¥983.04 Million ≈ $143.85 Million |
CN¥29.40 Million ≈ $4.30 Million |
0.030x | -74.00% |
| 2000-12-31 | CN¥204.83 Million ≈ $29.97 Million |
CN¥23.56 Million ≈ $3.45 Million |
0.115x | +424.44% |
| 1999-12-31 | CN¥156.83 Million ≈ $22.95 Million |
CN¥3.44 Million ≈ $503.34K |
0.022x | +152.29% |
| 1998-12-31 | CN¥104.29 Million ≈ $15.26 Million |
CN¥-4.37 Million ≈ $-640.11K |
-0.042x | -- |
About Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more